|
US2020330560A1
|
|
Lipid-based nanoparticles and methods using same
|
|
US2020323961A1
|
|
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
BR112020013460A2
|
|
compositions comprising lipid-based nanoparticles to treat diabetes mellitus
|
|
KR20190124269A
|
|
Stable Lipid-Based Nanoparticles
|
|
AU2015249189A1
|
|
Lipid construct for delivery of insulin to a mammal
|
|
AU2012247063A1
|
|
Lipid construct for delivery of insulin to a mammal
|
|
WO2011022396A1
|
|
Lipid construct for delivery of insulin to a mammal
|
|
US2010080773A1
|
|
Orally Bioavailable Lipid-Based Constructs
|
|
KR20160005130A
|
|
Orally bioavailable lipid-based constructs
|
|
HUE039023T2
|
|
Lipid construct for delivery of insulin to a mammal
|
|
US2011135725A1
|
|
Lipid Construct for Delivery of Insulin to a Mammal
|
|
AU2006249479A1
|
|
Lipid construct for delivery of interferon to a mammal
|
|
ZA200710056B
|
|
Lipid construct for delivery of interferon to a mammal
|
|
AU2006249480A1
|
|
Lipid construct for delivery of insulin to a mammal
|
|
CA2864366A1
|
|
Lipid construct comprising an amphipathic lipid, cholesterol, dicetyl phosphate, and a hepatocyte receptor binding molecule
|
|
US2006222698A1
|
|
Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
|
|
US2007218117A1
|
|
Supra molecular construct for delivery of interferon to a mammal
|
|
US2001021390A1
|
|
Prolongation of chemical activity of flavorants and therapeutics on mucin coated surfaces using mucin adhering amphiphilic substances
|
|
AU1921900A
|
|
A polysome
|
|
AU4090299A
|
|
Liposomal delivery complex
|
